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ABSTRACT

RETROVIRAL ANTIBODIES
Lisa S.

IN WILD-CAUGHT NEW WORLD PRIMATES.

Ragen and Francis L.

Black.

Epidemiology and Public Health,
Medicine,

New Haven,

Department of

Yale University School of

CT.

Sera from 387 wild-caught Brazilian monkeys were
for HIV-1

and related retroviral

antibodies.

screened

Serological

reactions with HIV-1 ELISA were observed in 4.6% of these
New World primates.
partial

The reactions were confirmed by

reactions in HIV-1 Western Blot and HIV-2 Radio

Immune Precipitation Assays.

The positive sera came from

animals caught in diverse parts of the Amazon Basin and
from five of eight species.

These results

suggest that

one or more viruses related to HIV-1 may be indigenous to
South America.

Isolation of the virus or viruses is

necessary to confirm these initial

findings.
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INTRODUCTION AND LITERATURE REVIEW

Introduction
Following the
tropic

retrovirus.

(HIV-1),1

1983 discovery of the T-cell

Human Immune Deficiency Virus type

1

presumed to be the cause of the Acquired Immune

Deficiency Syndrome

(AIDS)

in humans,2

there has been a

widespread search for related retroviruses throughout the
world.

Much of this research has focused on Africa where

infection with retroviruses occurs both in human and non¬
human primates.

Recent studies report the presence of

antibodies to HIV-1
Venezuala3
however,

in indigenous South American people in

and Brazil.4

There

is no previous evidence,

for the existence of HIV-1 or a related

retroviral

infection in New World primates.5'6

This

study

of sera from 387 Brazilian monkeys was designed to screen
a large number of New World primates for HIV-1
retroviral

and related

antibodies.

The Retrovirus Family
The Retroviridae family is composed of three
subfamilies of animal viruses that contain an RNAdependent DNA polymerase.

The viruses use this unique

viral enzyme known as reverse transcriptase to copy their
RNA genome into DNA.

The retrovirus virions are 80 to

2

130 nm in diameter and consist of an inner electron dense
core

surrounded by an outer envelope.

containing envelope

This

forms when the virus buds from the

plasma membrane of its host cell.

All

retroviruses

require three basic genes for replication:
viral

lipid-

internal core proteins,

pol,

gag for the

the polymerase or

reverse transcriptase gene,

and env for the envelope

glycoprotein.

order in all

retroviruses is

repeat

sequences on both

gag-pol-env.

The 5'

to 3'

Long terminal

(LTR)

ends of the virus genome code for transcription-initiation
sequences.

Other control genes exist at variable

sites on

the genome.
In spite of a gross morphogenesis common to
all

retroviruses,

there are differences in biochemical,

fine morphological,

and biological properties which allow

division into three subfamilies:
Oncovirinae,

and Spumavirinae.

Lentivirinae,
Lentiviruses are

exemplified by the prototype Visna virus,

known to cause a

slow inflammatory disease in sheep and an ability to kill
cells in vitro.

The oncoviruses,

intercisternal types A,
oncogenic

action.

B,

C,

further divided into four

and D,

have a potential

Spumaviruses cause inapparent disease

in animals and induce foamy degeneration in cultured
cells.7

for

3
Retroviruses in Humans
Prior to the discovery of HIV-1,

the only

known human retroviruses were Human T-cell Leukemia Virus
type

1

(HTLV-I)

potential

and type 2

(HTLV-II),

both with oncogenic

and similar to type C oncoviruses.

strongly associated with adult T-cell

HTLV-I

is

leukemias.8,9

HTLV-II was first detected and isolated in cultured cells
from a patient with hairy cell

leukemia.10

In 1986,

the

discovery of two more human retroviruses was announced.11
Human Immune Deficiency Virus,

type 2

(HIV-2,

named Lymphadenopathy Associated Virus-II,

previously

LAV-II)

was

originally isolated from two West African AIDS patients.12
Human T-cell Lymphotropic Virus,

type

IV

(HTLV-IV)

was

reported to be found in healthy Senegalese people and
appeared not to be associated with immune
deficiency.13*14,15

Subsequent molecular cloning of

HTLV-IV revealed it to be nearly identical to the Simian
Immunodeficiency Virus

(SIV)

to be discussed below;16

HTLV-IV is now believed to be a laboratory contaminant of
one of the original SIV isolates.17,18
however,

is prevalant in West Africa.

HIV-2

infection,

HIV-2 has served as

a source of antigen for extensive human surveys that

|

revealed high antibody prevalence in western Sub-Saharan
Africa.
Molecular cloning permitted sequence
analysis of HIV-2

that demonstrated its existence as a

4
unique

retrovirus related to but distinct from HIV-1.19

Epidemiologic
HIV-2

investigation in West Africa

suggests that

can cause AIDS independent of HIV-120’21;

comparison of HIV-1

and HIV-2

Africa demonstrate that HIV-2

but

seropositive populations in
is much slower to progress

from inapparent infection to generalized lymphadenopathy
or AIDS Related Complex

(ARC)

Further seroepidemiologic

syndromes,

is

infected people.22

studies confirm differences in

the morbidity rates of HIV-1
seropositivity,

in HIV-2

and HIV-2.

HIV-1

highly correlated with AIDS or AIDS-like

seen at high rates in Central Africa,

rare in West Africa.

HIV-2,

on the other hand,

primarily seen in West African countries and is

but is

is
less

frequently associated with AIDS.23*24
Pending further investigation of HIV-2,
HIV-1

remains the virus of major concern behind the AIDS

epidemic;

its classification,

structure,

and relation to

other retroviruses are of paramount importance in the
search for AIDS vaccines.26

It was initially thought that

HIV-1 would prove to be most closely linked to HTLV-1
HTLV-2

and thereby belong to the oncovirus

and

subfamily.

These three retroviruses have many important properties in
common.

They are human,

exogenous,

infectious

retroviruses isolated from mature T-cells with a
particular T4 tropism.
and impair T-cell

They induce

syncytial

function in vitro and cause

formation

5
immunosuppression in vivo.
similar size and there are

The major core proteins are of
stretches of nucleotide

sequence homology most noticeable in the qaq-pol
and LTRs.2*26

There also appears to be

region

serological cross¬

reaction between HTLV-1 and HIV-1.27
Upon discovery of the HIV-1 nucleotide
sequence,28’29,30
appears that HIV-1
subfamily.31’32,33
HIV-1

and that of Visna virus,31

Similarities between Visna Virus and
region between pol

not found in other retroviruses32

gag-pol

it

is a member of the Lentivirus

include a shared central

nucleotide

however,

and env

and remarkable

sequence homology particularly strong in the

region.33

HIV-1

and lentiviruses are unique among

retroviruses in possessing high molecular weight envelope
proteins.34
Lentivirus

In addition,
subfamily,

Anemia virus

(EIAV),36

persistent infection.
in HIV-1

at least two members of the

Visna virus36

and Equine

Infectious

show antigenic variation during
Genetic variability has been found

as well,13’37,38’39

but it is not yet clear if

this diversity of genomic expression is a lentivirus

sub¬

family trait.
Knowledge of the genetic

sequences of human

retroviruses has shed light on their protein structures
and actions.

HIV-1 has a complex genome

structure which

codes for at least six major proteins or polyprotein
precursors as depicted schematically in Figure

l.40*41
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There

are also four or five genes coding for non-

structural proteins,
and env genes.42

two of which are

located between pol

The gag gene codes for a polyprotein

with a molecular mass of about 55 kilodaltons
polypeptide,
and p25.

p55,

(kD).

This

is a precursor of two core proteins,

pl8

The pol gene codes for the reverse

transcriptase,

endonuclease,

and protease actions of the

virus represented by p68 and p34.
genes are called sor and tat,

The third and fourth

for short open reading frame

and transactivation of transcription respectively.

Tat

may activate transcription of viral genes and regulate
transcription of some cellular genes;28
necessary for cell death.43

it appears to be

The primary HIV-1 envelope

gene product is a 160 kD glycoprotein that is processed to
gpllO and gp41.

Gp41

is the transmembrane protein which

joins the envelope to the virus core.44
patients have antibodies to gpllO34
the other major structural proteins,
envelope.

The final

Nearly all AIDS

in addition to most of
both core and

area before the 3'

LTR is designated

orf for open reading frame.
There is substantial cross-reactivity
between many of the viral
Western Blot
(RIPA)

(WB)

or Radio

antigens of HIV-1 and HIV-2.24
Immune Precipitation Assay

confirmation has been used to distinguish between

these two viruses based on the thought that serological
cross-reactivity was primarily restricted to the major

7
core proteins.

For example,

HIV-2

env glycoproteins were

not immunoprecipitated by HIV-1 positive
however,

sera in one

study.19

Recent evidence,

and HIV-2

cross reactivity in WB may be far more common

than originally believed.45

suggests that HIV-1

Gpl40,

p36,

p26,

and pl6 are

the major HIV-2 proteins identified in RIPA and correspond
to HIV-1 proteins gpllO,
their basic
is

p34,

p25,

and pl8.

structure is the same,42

Although

the genome of HIV-2

less than 50% homologous with that of HIV-1.

Comparison of sequences reveals a 52% homology in the gag
region,

55% in pol,

and 35% in env for a weighted average

of 43%.46

Retroviruses in Primates
It is now recognized that T-lymphotropic
retroviruses closely related to HIV-2
non-human primates.

To date,

infect Old World

there are no reports of

antibodies to any of the HTLV or HIV retroviruses in New
World primates.

In one

study,

fifty-five sera from four

families of New World monkeys were found seronegative for
HTLV-1,5

and in another survey,

thirty-five sera from two

New World primate families were negative.6

A Medline

search found no evidence of simian AIDS infection in New
World primates.47

As of late

1987,

Hayami

et al report

the absence of HIV-1 or related antibodies in their
surveys of New World monkey sera.48

Two retroviruses have

8
been previously isolated,
Saimiri
M534.

scieureus:

however,

from the New World

Squirrel Monkey Retrovirus

(SMRV)

and

As these are grouped under the Oncovirus type D

heading,49’60

there appear to be no known lentiviruses in

New World primates.
Serologic
however,

do

studies in Old World primates,

show evidence for HIV-related retroviral

infection in several

species.

Antibodies to HTLV-1

in

non-human primates were first discovered in Japanese
macaques.61

They have since been identified in a variety

of species of Old World primates in Africa and Asia.6*6
Species of the genus Macaca have been thoroughly studied;
in a survey of 703

sera from ten species of monkeys,

the

frequencies of seropositive apparently healthy macaques
ranged from 10 to 50%.6

The genus Cercopithecinae has

also received much attention;

one study found 32/53

healthy Cercopithecus aethiops,
be HTLV-1

antibody positive.6

healthy monkeys,

HTLV-1

African Green Monkeys,

to

In addition to studies in

antibodies have been found in

association with malignant lymphoma or lymphoproliferative
disease in captive macaques.

One study found 11/13

macaques with naturally occurring lymphoid neoplasms to be
HTLV-1

antibody positive in contrast to 7

seropositive of

95 healthy macaques.62
A virus

similar but not identical to HTLV-1

has been isolated from HTLV-1

seropositive primates and is

9
known as Simian T-cell

Lymphotropic Virus

This monkey virus has the
pol-env-pX-LTR,

same genome

(STLV).53,54

structure,

as the human retroviruses.

LTR-qaq-

Analysis of

the env-pX-LTR region shows a 90% homology between STLV
and HTLV-1.5 5
More recent studies in Old World primates
have isolated a new simian retrovirus similar to HIV-1
HIV-2.

Now named Simian Immune Deficiency Virus

and

(SIV-

previously referred to as Simian T-cell Lymphotropic Virus
type 3,

STLV-III),

macaques,56,67

African Green Monkeys,58

and mandrills.48
HIV-1

this retrovirus has been found in
sooty mangabeys,89

SIV was initially found to be related to

and HIV-2 by the antigenic properties of its

proteins and by its biological properties including
cytopathic effect and tropism for T4 cells.56•57■8 8 * 8 9
appears to be associated with immune deficiencies
to AIDS in the macaques,58,59,60
Green Monkeys60

similar

but not in the African

or mangabeys.59,60

SIV infection can even

transmit immune deficiencies in macaques;
inoculated into

It

SIV„AC

was

six healthy rhesus monkeys producing an

AIDS-like disease in four of them.61

Figure 2

illustrates

the evolutionary relationships of the Old and New World
primates with SIV isolates

located according to the genus
I
I

in which they were discovered.62,63
!
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SIV is clearly related to HIV-1
RIPA analysis of SIVMAC
of 160,

120,

55,

demonstrates SIV specific proteins

and 24 kD similar in size to the HIV-1

major gag and env proteins.5®
sequence analysis of SIVAOM
general gene

Subsequent nucleotide

verified that it has the

gene.66

same

structure as HIV-1 except for truncation of

the two transmembrane glycoproteins.64
HIV-2,

and HIV-2.

SIVAOH

Like HIV-1 and

contains the functional transactivator tat

Sera from sooty mangabey monkeys and from SIV9H

inoculated rhesus monkeys showed strong reactivity to the
major viral

antigens of HIV-2.

positive sera reacts
envelope SIVsn

Likewise,

human HIV-2

specifically with the core and

antigens.66
Nucleotide sequence analysis of SIV reveals

that SIV is more closely related to HIV-2 than to
HIV-1.46*67*6®

When the SIV env gene is compared to the

env gene of several HIV-1 isolates,
45% homology;

SIV and HIV-2 homology in the same region is

approximately 70%.6®

Other areas correlate for an overall

72% homology between SIVAO„
between SIVAO„

the sequence shows 35-

and HIV-1.44

and HIV-2

and a 43% homology

Studies of SIVnAC

reveal

comparable sequence homology percentages wih HIV-1 and
HIV-2.

For example,

homologous with HIV-2

the SIVnAC

pol gene is 83.6%

and 59% with HIV-1,

again suggesting

a closer relationship between SIV and HIV-2.67
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Evolution of Retroviruses
Such comparisons of sequence homology have
allowed investigators to
retroviruses.

speculate on the evolution of

Genealogical trees have been constructed

based on knowledge of genetic data,
characteristics,

morphological

and protein cross-reactivity.

All

agree

on a common progenitor for the retroviruses with early
division between the oncoviruses and lentiviruses.
the

lentiviruses,

it appears that HIV-1,

HIV-2,

Among

and SIV

diverged more recently than did Visna and the other
ungulate lentiviruses,
Encephalitis virus

EIAV and Caprine Arthritis

(CAEV).

Similarly,

diverged more recently than HIV-1
presents a retroviral

HIV-2

and SIV

and HIV-2.24

Figure 3

family tree consistent with current

information. 2 6*31*32*6B*69
The presence of similar retroviruses in
humans and primates has

led to controversy over the

possibility of interspecies transmission.

The unique

distribution of HTLV-1

led Gallo et al to form an

intriguing hypothesis;

they described the origin of HTLV-1

infection in Africans from contact with infected Old World
primates and the

subsequent spread of HTLV-1 infection to

Japan via Portugese
more information,
discounted.71

seamen in the

16th century.70

With

this theory appears to have been

After the characterization of STLV-1,

12
Komuro et al

state that

"the ancestor virus infected

simians and humans independently,

and has been preserved

in their species with slight modification during their
developmental process.
monkeys to humans,

if in fact it occurred,

been a recent event."64
same research group,
HIV-2,

and SIV;

distant past,

Transmission of the viruses from

In 1987,

Hayami,

could not have
a member of the

extended this opinion to HIV-1,

he acknowledges a common ancestor in the

but believes that they evolved independently

in their respective species.4®

Kanki

et al agree and

state that the greater similarity between different HIV-2
isolates than between HIV-2

isolates and SIVAOH

is

compatible with their development in different species.24

Retroviruses in South America
Regardless of questions concerning the
precise connection between HIV-1,

HIV-2,

and SIV,

no doubt that they are closely interrelated.

there is

The recent

discovery of antibodies to HIV-1 and related retroviruses
in indigenous South American people raises the possibility
of HIV-1 or related retroviral infection in South American
monkeys.

The South American findings include the presence

of HIV-1 or related retroviral antibodies in Venezualan,3
and Brazilian Indians.4

In Venezuala,

9/224 isolated

Amazon Indians were found positive for HIV-1
Immunoflouresence,

WB,

and RIPA.3

In 17/25

antibodies by
isolated South

13
American Indian tribes,

91/2441

serum specimens reacted

positively in HIV-1 ELISA tests.
positive

All of twelve HIV ELISA

sera reacted in HIV-1 WB,

but only one with the

characteristic pattern of bands in HIV-1
As mentioned earlier,

infection.4

however,

there is no

previous evidence for the presence of HIV-1 or related
retroviral

infection in New World primates.

Given the

existence of SIV in Old World primates and its close
relationship to human retroviruses,

the discovery of HIV-1

infection in indigenous South American people provided the
impetus for this

study of 387 South American monkey sera.

These monkey sera were

screened for antibodies to HIV-1 on

the hypothesis that an HIV-1
exists in New World primates.

related retroviral

infection

14

MATERIALS AND METHODS

Specimens
The

specimens tested were from two

collections of wild-caught primate

sera in Brazil.

211

specimens were from Instituto Evandro Chagas in Belem,
Brazil.

These specimens were collected from 1970 to 1985

from the Amazon region and include nine genera distributed
as follows:
Callicebus
Saguinus

Alouatta
(1),

(8),

Cebus

(70),

Aotes

(82),

and Saimiri

(7),

Chiropotes

(4).

176

Ateles
(21),

(17),
Pithecia

(1),

serum samples were

from a collection at the University of Para.

These

specimens are all Alouatta and were collected from the
Tucurui

reservoir area on the Tocantins river in 1983.

Figure 4 illustrates the location of the collection sites.
All monkeys were apparently healthy at the
time of capture,

though not thoroughly examined.

Between

collection and testing the sera were stored at -40°C,
may have been transiently thawed for testing.

but

15
Serological Tests
1)

ELISA
The initial

was conducted at

screening of 387 primate sera

Instituto Evandro Chagas in Belem,

using the Electronucleonics ELISA kit.
purified inactivated HIV-1

Brazil

In this test

from the H9 cell

adsorbed onto wells of a microassay plate.

line is
Any HIV-1

antibodies in sera samples form stable complexes with
HIV-1

antigens on the plate.

Goat anti-human IgG labeled

with peroxidase binds to the antigen-antibody complex and
color develops in positive wells after the addition of an
enzyme substrate.72

This kit was used according to

manufacturer's instructions with the replacement of
peroxidase-conjugated anti-human IgG by peroxidaseconjugated Protein A.
Protein A is a S.
which binds to the F0
all mammalian species.

aureus cell wall protein

portion of immunoglobulins of nearly
The Protein A ELISA protocol was

established on the basis of three procedures:
Immunodiffusion,

HIV-1 ELISA comparison tests between

Protein A and anti-human IgG,

and Whittaker M.A.

Bioproducts MEASLELISA comparison tests between Protein A
and anti-human IgG on New World monkey sera.

The

immunodiffusion demonstrated only partial cross-reaction
between anti-human IgG and the primate sera.
ELISA comparison tests

The HIV-1

showed greater reproducibility with

16
Protein A than with anti-human IgG.
however,

The MEASLELISA tests,

were the most conclusive in the

selection of

Protein A over the Electronucleonics conjugate.
MEASLELISA tests were run on pre-vaccination and three
weeks post-vaccination New World monkeys given the measles
vaccine.

With hemagglutination inhibition as a reference,

the Protein A results proved to be far more accurate than
the anti-human IgG results.
anti-human IgG.)

(See Results;

Protein A vs.

The Protein A was used at a dilution of

1:12000 to correlate closely with the given control values
of the Electronucleonics kit.
The Burroughs-Wellcome

"Wellcozyme"

competitive ELISA test was also used in the initial
screening process on 78 sera previously tested with the
Electronucleonics kit.

The Wellcozyme test microwells are

coated with inactivated HIV-1 antigen that has bound to
purified HIV-1 antibodies previously attached to the
wells.

Sera samples incubate in the wells with

peroxidase-conjugated anti-HIV-1;
the

antibodies to HIV-1 in

samples compete with the conjugate for binding to the

HIV-1

antigen.

The amount of color in each well after the

addition of the enzyme substrate is inversely proportional
to the concentration of HIV-1
It is

antibody in the sample.73

said by the manufacturer to be more antigen specific

than the ELISA test.

The Wellcozyme kit was used

according to manufacturer's instructions.
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2)

Western Blot
Western Blot tests were run to confirm

positive direct ELISA results.

Diagnostics Pasteur WB kit

was used at Institut Pasteur according to manufacturer's
instructions.

Inactivated HIV-1 viral proteins were

separated by polyacrylamide gel electrophoresis and
transferred onto a nitrocellulose sheet.

Nitrocellulose

strips were saturated with non-fat milk to prevent non¬
specific reactions and then incubated with serum
specimens.

HIV-1 antibodies bind to viral

antigens and

are detected by the addition of peroxidase-labelled sheep
anti-human IgG and enzyme

substrate.

Bands stained

specifically for known viral proteins allow determination
of antibodies.40,41

3)

Radio

Immune Precipitation Assay
Sera found positive for at least one HIV-1

protein on WB were further tested for HIV-1

and HIV-2

specific proteins by the RIPA procedure as developed at
Institut Pasteur.

HIV-1 and HIV-2

labelled with 36S cysteine.
3 6 S cysteine

(200uCi/ml)

infected cells were

These cells were exposed to

by incubation overnight at 37 C.

Clarified supernatant was centrifuged at 100,000g for 100
minutes at 4°C.

The pellet was

containing 50mM TRIS-HC1 pH 7.4,

lysed in a RIPA buffer
150mM NaCl,

ImM EDTA,

18
1% Triton X-100,

0.1% sodium deoxycholate,

lauryl

The

sulfate.

0.1% sodium

lysate was diluted to yield SBS

antigen at 100,000 cpm.

50ul of the diluted virus lysate

was incubated overnight with 5ul of each serum sample at
4°C.

Immune complexes were adsorbed on Protein A-

Sepharose CL-4B and analyzed by electrophoresis on sodium
dodecyl

sulfate-polyacrylamide gels

(SDS-PAGE).

Gels were

dried and exposed to x-ray films in order to visualize the
radioactive proteins.

Evaluation of Results
ELISA results were judged to be negative,
borderline,

or positive.

As the initial

screening process

was designed to survey a large number of possible positive
specimens,
were all

borderline positive results were retested as

sera meeting the manufacturer's criteria for

positivity.

The term ELISA positive is used here to refer

to sera that were positive in one assay and positive or at
least borderline in a repeat test.
WB results were evaluated specifically for
each retroviral protein and not for HIV-1 presence or
absence.

The criteria for HIV-1 positive WB results in

humans vary,

as mentioned in the Discussion.

Moreover,

the goal of this study was the detection of serological
evidence of HIV-1 or related retroviral
only HIV-1

itself.

Therefore,

infection and not

the presence of any HIV-1

19
proteins was considered significant.
RIPA results were also recorded by presence
of HIV-1 or HIV-2 proteins for the

same reason.

20

RESULTS
Protein A vs.

anti-human IgG
The MEASLELISA and Hemagglutination

Inhibition

(HI)

tests run on the monkey sera drawn prior

to vaccination were conclusively negative.
after the vaccination of the monkeys,
retested.

Using HI

as a reference.

Three weeks

the sera were

Protein A and anti¬

human IgG were compared in the MEASLELISA test.

HI

showed

the post-vaccination sera to be markedly positive in all
monkey sera:

>1

:

256.

The anti-human IgG results showed

the post-vaccination sera to be,

on average,

10.7% of the

positive control whereas the Protein A tested sera were
58% of the positive control.

ELISA Reactions
Eighteen of 387 primate sera screened by
HIV-1 ELISA with Protein A tested positive in two separate
tests or positive and borderline in two separate tests.
The distribution by genus is

shown in Table 1.

Five of

the positive sera were from the Tocantins river Alouatta
collection at the University of Para.
were from the collection at

The remaining 13

Instituto Evandro Chagas and

were from a wide distribution of locations within the
Amazon.
The indirect ELISA results were uniformly

21
negative for the 78

sera tested.

These 78 include all

18

sera found positive or reactive by HIV-1 direct ELISA.

Western Blot Results
Thirty sera including 10 of the

18

originally positive by HIV-1 ELISA were tested by HIV-1
Western Blot.

The

sera supply of 8 originally positive

samples had been depleted in previous tests.

12

sera were

positive for at least one major protein including four of
the eight ELISA positive
6 positive reactions.
shown in Table 2
control
pl8.

sera.

Figure 5 is a photograph of

Individual

for these 6

results by genus are

specimens.

The negative

shown in Figure 5 had a trace positive reaction at

Results as interpreted in Table 2 with trace,

++ take this negative control

into account.

+,

or

Eighteen sera

were completely negative or had trace bands only.

RIPA Results
Seventeen sera,

including the 12

positive for at least one HIV-1 protein on WB,
by RIPA for HIV-1.
proteins.

found
were tested

No sera were found positive for HIV-1

Twenty-eight sera were tested for HIV-2

antibodies;

one

sera,

PR1682,

from a Cebus monkey,

showed

evidence of a glycoprotein between gpllO and gpl60 and a
band at p26.
results.

Figure 6 is a photograph of the HIV-2 RIPA

It should be noted that intensity of bands is
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key to determining positive results in this RIPA test.
The faint bands on the negative control
intensity to the bands on the
negative.

are similar in

sera samples judged to be

23

DISCUSSION

Sources of error must be considered before
the results of this
positive

(FP)

study can be discussed.

rate is of much publicized concern in the

use of HIV-1 ELISA as a screening test.74
HIV-1 ELISA kits,
here,

The false

Six commercial

not including Electronucleonics used

were found to have FP rates from 0 to 0.42%.76

rate is

low when the purpose for which the tests were

developed is taken into consideration.
produced in order to
antibodies,
enhance

This

As they were

screen donated blood for HIV-1

the system is overloaded with antigen to

sensitivity at the expense of specificity.76
In addition,

there are certain illnesses

which are known to predispose sera to FP reactions:
autoimmune diseases with circulating antibodies to HLA,
nuclear,

and other cellular antigens,

acute viral diseases

such as cytomegalovirus and Epstein-Barr infections with
cross-reacting antibodies,
with liver disease,

immune dysfunction associated

lymphoproliferative disease and

multiple myeloma with hypergammaglobulinemia,

adult T-cell

leukemia with cross-reactive HTLV-1 antibodies,
recurrent malaria with anti-lymphocyte,
other auto-antibodies.41,76'77

and

anti-nuclear,

and

Certain healthy people are
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also

susceptible to FP HIV-1 ELISA reactions including

people with anti-HLA-DR4 such as multiparous women or
patients with transfusion-induced antibodies

specific for

the class

II major histocompatibility antigens present in

the

scale manufacture of HIV-1.76*78

large

treatment,

prolonged storage of sera,

Finally,

heat

and procedural

errors while using the ELISA kits may lead both to FP and
false negative

(FN)

reactions.41

Other FN reactions are found in AIDS
patients who have a decreased antibody titer in late stage
disease and in pre-AIDS patients who do not have
detectable antibody for six weeks after the initial
infection.41

ELISA FN reactions have also been reported

in patients taking immunosuppressive drugs who are found
to be HIV-1 positive by confirmatory tests.79
While most of these examples pertain
specifically to humans,

they nonetheless illustrate the

extent of FP reactions in commercial ELISA kits and
justify the use of confirmatory tests on all HIV-1 ELISA
positive

sera.

This

study includes the additional

complicating factors of using monkey sera and Protein A,
so the frequency of FP reactions may be higher.
expected FP rate is not possible to calculate,
because of these unknowns as well

ELISA FPs in mind,

however,

as variations in FP

rates noted even among different runs of the
manufacturer's kit.80

The

same

With the information concerning

the initial design of this study
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followed standard procedure for human studies in that all
initially positive ELISA sera were retested and only those
reactive in both tests were then confirmed by Western
Blotting.
WB is the most common confirmatory test for
the presence of HIV-1

antibody and the

which other techniques are compared.

standard against
It has been recently

recognized,

however,

that Western Blots have also produced

FP results;

differences in interpretation and a lack of

standardization in criteria for positivity and negativity
account for many of these.74

Biberfield et al describe

the appearance of bands for p24 and p55 in HIV-1 negative
individuals and suggest that this phenomenon is due to
cross-reactions with normal cell constituents such as
ribonucleproteins or to the presence of other human
retroviruses.81

Couroce et al found eight sera with the

same p25-p55 pattern and 23 with pl8 and p55 in screening
151,667 blood donors.

These 31

HIV-1 and HIV-2 RIPA negative

sera were the only both

specimens out of their 130

WB positive sera and were therefore thought to be
negative.82

Similar atypical WB results have been

reported by Dock et al who,

in contrast,

believe the

unusual WB reactivity is directed against retroviral core
proteins.83

These examples lend credence to the belief

that WB results are
interpretation."4 1

"open to considerable operator
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Others

(Roy et al)

stress caution in

interpreting WB for HIV-1 while describing a woman with
positive ELISA and positive WB who was found to be HIV-1
negative by a different ELISA test and by negative
isolation on a later occasion;

they traced the FP to a

reactivity to antigens from the cultured human cells in
which the HIV-1 had grown.84
laboratories by the U.S.
HIV-1 WB.

A study of commercial

Army found 85-100% accuracy in

Four out of five

labs reported at least one FP

result out of 15

specimens;

normal

leading the authors

specimens

all FPs were on different
(Burke et al)

to

believe the errors were due to technique and not to
intrinsic biologic properties of the sera.85
The WB FP controversy primarily concerns the
lack of agreement on which proteins are necessary to
diagnose HIV-1

infection.

limited to HIV-1

infection,

This study,

however,

but concerned instead with the

presence of HIV-1 or any related retrovirus.
results were reported by protein,
or negativity,
FP reports.

was not

Western Blot

not by HIV-1 positivity

thus avoiding one of the

sources of HIV-1

The partial positive results reported here do

not satisfy the current criteria for HIV-1 infection in
humans,

but positive results may still be significant.

Moreover,

all

sera positive by WB for at least one major

HIV-1 protein were tested for the presence of both HIV-1
and HIV-2 by RIPA,

an acknowledged confirmatory test.

The
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RIPA offers the

lowest chance of false reactions in that

it does not depend on anti-human sera and yet resolves
reactions to individual proteins.
With the above information on possible
sources of error in mind,
discussed.
primate

the results may now be

In the initial tests,

4.6% of the New World

sera tested here were initially positive by HIV-1

direct ELISA

(Table

repeat tests.

1).

These results were confirmed in

Five of these specimens were from the

Tocantins Alouatta collection and the other 13
distributed locations
Tucurui

(Oriximina,

reservoir area)

Santar^m,

and several

from widely

Goias,

species.

and the

The

reproducibility of the tests and subsequent partial
confirmation by WB and RIPA indicate that these reactions
are more than an artifact of chance,

in spite of the

uniformly negative Wellcome kit ELISA results.

Negative

results by Wellcozyme may be explained by the fact that
this kit is a competitive ELISA test and is consistently
more specific and less prone to register reactions with
cross-reacting antibodies than the direct ELISA.

It has

been suggested that partly cross-reacting antibodies may
not be able to compete with simultaneously added HIV-1
antibodies.

This theory has been used to explain HTLV-IV

antibody positive sera found negative by the HIV-1
Wellcome kit.86
The direct ELISA results are to be
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considered while remembering the forementioned study of
six commercial ELISA kits

showing a range of false

positive reactions of 0 to 0.42%.74
positive

specimens in this

The proportion of

study is therefore more than

ten times that expected of non-specific reactions.

The

most relevant source of FP reactions is chronic malaria
which occurs in South American monkeys.87

Because the

sera used had been collected at earlier dates,

it was not

possible to examine matched blood smears for plasmodia.
More worrisome in evaluating the HIV-1 ELISA is our
limited experience with protein A in place of the usual
anti-human reagent.

Production of peroxidase conjugated

sera specific for each simian genus would be needed to
circumvent this problem.
The partial positive reactions to HIV-1 and
HIV-2 virus

specific proteins in WB and RIPA suggest the

possibility that immunity to a retrovirus is present in
the New World monkeys.

Twelve of 30 sera reacted at the

site of at least one major viral protein band by WB.
None reacted with all viral proteins.
including those positive by WB,

were tested by HIV-1 RIPA,

but no protein bands were found.
for HIV-2

antibodies by RIPA,

near

57 W,

IS,

Seventeen sera,

Of the 28

one,

showed bands at the

sera tested

from a Cebus captured
location of p26 and

near gpllO.
If one makes the assumption that the

29
immunizing agent is not HIV-1,

the failure to find

positive rections in the indirect test is not unexpected
because of the greater specificity of this test as
described earlier.

Similarly,

WB reactions may be due to
and the infecting agent.
tests may be

failure to obtain complete

limited analogy between HIV-1
An additional

factor in the WB

limited cross reactions between simian and

human immunoglobulins in their reaction with the goat
anti-human serum which was not replaced,
with Protein A.

in this test,

Although no one monkey serum reacted with

a full

spectrum of viral bands,

the diversity of reactions

in the

set of sera was broad enough that it is difficult

to account for them by postulating reaction with foreign
antigens in the WB virus preparation.
reactions are with the gag proteins,

The most prevalant
as would be expected

of antibody to an HIV-related virus.
The RIPA results were similar to the WB test
in that a full

spectrum of viral proteins did not react

with the monkey sera.

In fact,

gave an atypical pattern.

the one positive serum

(See Figure 6.)

The fact that

the RIPA HIV-1 tests were entirely negative but that the
RIPA HIV-2

reacted conforms with the generally more

central position of HIV-2

in the

spectrum of primate

retroviruses.
This study provides

suggestive evidence that

one or more Lentiviruses is broadly distributed in New

30
World primates.

The postulated virus or viruses relate

more closely to HIV-2

than HIV-1.

permit distinction between the

simian agent and the agent

that elicits HIV antibody in humans
general

area.

The current data do not

living in the

same

Isolation of the virus or viruses is

necessary to confirm these initial

findings.
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Table

1:

HIV-1

Genus

ELISA results by Genus

no.

Alouatta
Aotes
Ateles
Callicebus
Cebus
Chiropotes
Pithecia
Saimiri
Saguinus

tested
246
7
17
1
82
21
1
4
8

TOTAL

387

Table

1:

no.

positive

%

positive

10
1
3
0
3
0
0
0
1

4.1
14.3
17.6
0
3.6
0
0
0
12.5

18

4.6

HIV-1 ELISA results by Genus
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Serum

Genus

PR1009
PR1682
PR2045
PR2051
Ab456
PR2062

Alouatta
Cebus
Cebus
Alouatta
Alouatta
Alouatta

Band mobility in kD for HIV-1 proteins
pl8 p25 p34 p40 gp41 p55 p68 gpllO gpl60
+
++
tr
+
++
+
tr
tr
tr
+
++
+

tr = trace band present
+
= band present
+ + = band very strong

Table 2:

HIV-1 Protein Specific Antibody Detected
by Western Blot in 6 New World Primates
as

shown in Figure 5.
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Schematic representation of HIV-1 genome with
major protein translation products.

Suborder:

Anthropoidea

Family:

Genus:
34

Man

.Hominidae

/

Pongidae

r
Apes

/

-jHomo

Hylobatidae

/
Cercopithecidae

Simiae Catarrhin;
Old World Monkey/

Callithricidae

Macaca—SIVM7_
~
MAC
Papio—SIV
^
MND
Theropithecus
Cercocebus—SIV„W
SM
Cercopithecus--SIV

Presbytis
Pygathrix
Rhinopithecus
Simias
Nasalis
Colobus

Callithrix
Cebuella
Leontideus
Saguinus

, . .
. ,
limiconidae \
ICallimico
Aotes
Callicebus
Pithecia
Chiropotes
Cacajao
Alouatta
Cebidae
Saimiri
Cebus
Ateles
Brachyteles
Lagothrix

Simiae Platyrrhinae
New World Monkey:

/

/
1
40

Hylobates
Symphalangus

Erythrocebus

olobidae

Jc

Pongo
Pan
Gorilla

I
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I
20

"T
10

Millions of Years Ago
Figure 2:

Primate Evolutionary Tree

SIV isolates according to genus

AGM
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HIV-

type C

Mammalian

*<

T3

re

n

Figure 3:

Retrovirus Evolutionary Tree

Abbreviations as in text with the addition of:
BLV= Bovine Leukemia Virus
IAP= Intracisternal A Particle
MMTV= Mouse Mammary Tumor Virus
RSV= Rous Sarcoma Virus
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Figure 4:

Map of Brazil with sera collection sites

12345678
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160
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68

55
41
34
25

|
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Figure 5:
Lanes:

HIV-1 Western Blot tests with primate
1- positive control;

sera.

2- negative control;

3- PR1069;

4-PR1682;

8-PR2062.

Lane 4 carries serum from the Cebus that

was RIPA positive.

5-PR2045;

6-PR2051;

7-Ab456;
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I

2

3 4 5 6 7 3 9 10 II 12 13 14

Figure 6:
Lanes:

HIV-2 RIPA results

1-11 Alouatta sera;

13- positive control;

12-negative control;

14- Cebus

serum.

the major viral proteins in the control
be gpl40,

p36,

p26,

The

location of

are thought to

and pl6 as described in text.

9 •
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